口服亚单位SARS-CoV-2疫苗可诱导系统性中和IgG、IgA和细胞免疫应答,并能增强注射疫苗初免后的中和抗体应答
本研究开发了由SARS-CoV-2刺突蛋白受体结合域(RBD)、核衣壳蛋白(N)两个结构域及热不稳定肠毒素B(LTB)黏膜佐剂组成的口服多抗原疫苗。在小鼠中评估三剂口服免疫方案,在大鼠中评估皮下初免加口服加强的异源方案;小鼠口服疫苗较对照显著增强第三剂后病毒中和抗体、抗S IgG和IgA产生及N蛋白刺激的T细胞IFN-γ和IL-2分泌,大鼠口服加强较口服安慰剂加强诱导更高的中和抗体滴度。
要点
- 小鼠口服三剂疫苗较对照显著增强第三剂后中和抗体、抗S IgG和IgA及N蛋白刺激的T细胞IFN-γ和IL-2分泌。
- 大鼠经S1蛋白皮下初免后,口服疫苗加强较口服安慰剂加强诱导显著更高的中和抗体滴度。
- 两剂皮下初免后单次口服加强所诱导的血清IgG和黏膜IgA水平与三剂皮下接种相似。
核心结论
- 口服LTB佐剂多表位SARS-CoV-2疫苗触发多样的体液、细胞和黏膜免疫应答,可能提供保护,同时减少目前限制全球疫苗接种的技术障碍,无论用于初免还是加强程序。
研究设计与样本
- 研究开发口服多抗原SARS-CoV-2疫苗,由病毒S蛋白RBD、N蛋白两个结构域和LTB黏膜佐剂组成。
- 在小鼠中评估三剂疫苗接种方案,在大鼠中评估异源皮下初免加口服加强方案。
主要发现
- 小鼠口服疫苗较对照小鼠显示第三剂后病毒中和抗体、抗S IgG和IgA产生及N蛋白刺激的T细胞IFN-γ和IL-2分泌显著增强。
- 大鼠经病毒S1蛋白胃肠外初免后,口服疫苗加强较口服安慰剂加强引起显著更高的中和抗体滴度。
- 两剂皮下初免后单次口服加强引起的血清IgG和黏膜IgA水平与三剂皮下接种相似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rapid spread of the COVID-19 pandemic, with its devastating medical and economic impacts, triggered an unprecedented race toward development of effective vaccines. The commercialized vaccines are parenterally administered, which poses logistic challenges, while adequate protection at the mucosal sites of virus entry is questionable. Furthermore, essentially all vaccine candidates target the viral spike (S) protein, a surface protein that undergoes significant antigenic drift. This work aimed to develop an oral multi-antigen SARS-CoV-2 vaccine comprised of the receptor binding domain (RBD) of the viral S protein, two domains of the viral nucleocapsid protein (N), and heat-labile enterotoxin B (LTB), a potent mucosal adjuvant. The humoral, mucosal and cell-mediated immune responses of both a three-dose vaccination schedule and a heterologous subcutaneous prime and oral booster regimen were assessed in mice and rats, respectively. Mice receiving the oral vaccine compared to control mice showed significantly enhanced post-dose-3 virus-neutralizing antibody, anti-S IgG and IgA production and N-protein-stimulated IFN-γ and IL-2 secretion by T cells. When administered as a booster to rats following parenteral priming with the viral S1 protein, the oral vaccine elicited markedly higher neutralizing antibody titres than did oral placebo booster. A single oral booster following two subcutaneous priming doses elicited serum IgG and mucosal IgA levels similar to those raised by three subcutaneous doses. In conclusion, the oral LTB-adjuvanted multi-epitope SARS-CoV-2 vaccine triggered versatile humoral, cellular and mucosal immune responses, which are likely to provide protection, while also minimizing technical hurdles presently limiting global vaccination, whether by priming or booster programs.
引用
- Pitcovski J, Gruzdev N, Abzach A, et al. Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine. Vaccine. 2022. PMID: 35078662. doi:10.1016/j.vaccine.2022.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。